Peer-reviewed articleOpen access

Adverse Health Outcomes of Psilocybin, LSD, MDMA, Ibogaine, and 5-MeO-DMT.

Simonsson O, Bradley M, Black JC, Rockhill KM, Monte AA, Hendricks PS

JAMA network openSep 1, 2026License: open accessSweden0 citationsDOI: 10.1001/jamanetworkopen.2026.36756

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

PsilocybinMDMALSDIbogaineDMT5-MeO-DMT

View paper

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.

Related research

ArticlePsilocybin

Race and Gender Differences in the Moderating Relationship of Psychedelics on Stigma and Distress.

Viña SM

Europe PMC2025

ArticlePsilocybin

Psychedelics and Mental Health in Endurance Athletes: A Cross-Sectional Study in Brazil.

Portes MAM, Bertoglio LJ

Europe PMC2026

ArticlePsilocybin

Psychedelic experiences elicited by serotonergic psychedelics: Molecular mechanisms and functional connectivity changes in the brain.

Vollebregt R, Storm AEM, Lucassen PJ +1

Europe PMC2026